FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282925423> ?p ?o ?g. }

• W4282925423 endingPage "3857" @default.
• W4282925423 startingPage "3848" @default.
• W4282925423 abstract "PURPOSE The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone. We hypothesized that the addition of venetoclax to cladribine (CLAD)/low-dose araC (low-dose cytarabine [LDAC]) alternating with 5-AZA backbone may further improve outcomes for older patients with newly diagnosed AML. METHODS This is a phase II study investigating the combination of venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA in older (≥ 60 years) or unfit patients with newly diagnosed AML. The primary objective was composite complete response (CR) rate (CR plus CR with incomplete blood count recovery); secondary end points were overall survival, disease-free survival (DFS), overall response rate, and toxicity. RESULTS A total of 60 patients were treated; median age was 68 years (range, 57-84 years). By European LeukemiaNet, 23%, 33%, and 43% were favorable, intermediate, and adverse risk, respectively. Fifty-six of 60 evaluable patients responded (composite CR: 93%) and 84% were negative for measurable residual disease. There was one death (2%) within 4 weeks. With a median follow-up of 22.1 months, the median overall survival and DFS have not yet been reached. The most frequent grade 3/4 nonhematologic adverse events were febrile neutropenia (n = 33) and pneumonia (n = 14). One patient developed grade 4 tumor lysis syndrome. CONCLUSION Venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA is an effective regimen among older or unfit patients with newly diagnosed AML. The rates of overall survival and DFS are encouraging. Further study of this non–anthracycline-containing backbone in younger patients, unfit for intensive chemotherapy, as well as comparisons to standard frontline therapies is warranted." @default.
• W4282925423 created "2022-06-16" @default.
• W4282925423 creator A5000750846 @default.
• W4282925423 creator A5009316700 @default.
• W4282925423 creator A5010786159 @default.
• W4282925423 creator A5016368595 @default.
• W4282925423 creator A5020340537 @default.
• W4282925423 creator A5021380291 @default.
• W4282925423 creator A5028081179 @default.
• W4282925423 creator A5028845635 @default.
• W4282925423 creator A5029750735 @default.
• W4282925423 creator A5034799610 @default.
• W4282925423 creator A5035605515 @default.
• W4282925423 creator A5045242507 @default.
• W4282925423 creator A5046135731 @default.
• W4282925423 creator A5050975340 @default.
• W4282925423 creator A5051949215 @default.
• W4282925423 creator A5055045706 @default.
• W4282925423 creator A5059373442 @default.
• W4282925423 creator A5059600583 @default.
• W4282925423 creator A5061026876 @default.
• W4282925423 creator A5066894053 @default.
• W4282925423 creator A5079069209 @default.
• W4282925423 creator A5079262854 @default.
• W4282925423 creator A5085252830 @default.
• W4282925423 creator A5088307376 @default.
• W4282925423 creator A5090435894 @default.
• W4282925423 date "2022-11-20" @default.
• W4282925423 modified "2023-10-15" @default.
• W4282925423 title "Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia" @default.
• W4282925423 cites W1600365609 @default.
• W4282925423 cites W1926130940 @default.
• W4282925423 cites W2029409133 @default.
• W4282925423 cites W2092335024 @default.
• W4282925423 cites W2105501266 @default.
• W4282925423 cites W2106084333 @default.
• W4282925423 cites W2159507916 @default.
• W4282925423 cites W2288894655 @default.
• W4282925423 cites W2419140434 @default.
• W4282925423 cites W2760499085 @default.
• W4282925423 cites W2883399820 @default.
• W4282925423 cites W2886917823 @default.
• W4282925423 cites W2904410802 @default.
• W4282925423 cites W3013447738 @default.
• W4282925423 cites W3043154717 @default.
• W4282925423 cites W3048827006 @default.
• W4282925423 cites W3144004041 @default.
• W4282925423 cites W3164043037 @default.
• W4282925423 cites W3164441110 @default.
• W4282925423 cites W3183370518 @default.
• W4282925423 cites W4376595466 @default.
• W4282925423 doi "https://doi.org/10.1200/jco.21.02823" @default.
• W4282925423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35704787" @default.
• W4282925423 hasPublicationYear "2022" @default.
• W4282925423 type Work @default.
• W4282925423 citedByCount "25" @default.
• W4282925423 countsByYear W42829254232022 @default.
• W4282925423 countsByYear W42829254232023 @default.
• W4282925423 crossrefType "journal-article" @default.
• W4282925423 hasAuthorship W4282925423A5000750846 @default.
• W4282925423 hasAuthorship W4282925423A5009316700 @default.
• W4282925423 hasAuthorship W4282925423A5010786159 @default.
• W4282925423 hasAuthorship W4282925423A5016368595 @default.
• W4282925423 hasAuthorship W4282925423A5020340537 @default.
• W4282925423 hasAuthorship W4282925423A5021380291 @default.
• W4282925423 hasAuthorship W4282925423A5028081179 @default.
• W4282925423 hasAuthorship W4282925423A5028845635 @default.
• W4282925423 hasAuthorship W4282925423A5029750735 @default.
• W4282925423 hasAuthorship W4282925423A5034799610 @default.
• W4282925423 hasAuthorship W4282925423A5035605515 @default.
• W4282925423 hasAuthorship W4282925423A5045242507 @default.
• W4282925423 hasAuthorship W4282925423A5046135731 @default.
• W4282925423 hasAuthorship W4282925423A5050975340 @default.
• W4282925423 hasAuthorship W4282925423A5051949215 @default.
• W4282925423 hasAuthorship W4282925423A5055045706 @default.
• W4282925423 hasAuthorship W4282925423A5059373442 @default.
• W4282925423 hasAuthorship W4282925423A5059600583 @default.
• W4282925423 hasAuthorship W4282925423A5061026876 @default.
• W4282925423 hasAuthorship W4282925423A5066894053 @default.
• W4282925423 hasAuthorship W4282925423A5079069209 @default.
• W4282925423 hasAuthorship W4282925423A5079262854 @default.
• W4282925423 hasAuthorship W4282925423A5085252830 @default.
• W4282925423 hasAuthorship W4282925423A5088307376 @default.
• W4282925423 hasAuthorship W4282925423A5090435894 @default.
• W4282925423 hasConcept C104317684 @default.
• W4282925423 hasConcept C126322002 @default.
• W4282925423 hasConcept C143998085 @default.
• W4282925423 hasConcept C150194340 @default.
• W4282925423 hasConcept C185592680 @default.
• W4282925423 hasConcept C190727270 @default.
• W4282925423 hasConcept C197934379 @default.
• W4282925423 hasConcept C2776239401 @default.
• W4282925423 hasConcept C2776694085 @default.
• W4282925423 hasConcept C2777063308 @default.
• W4282925423 hasConcept C2777938653 @default.
• W4282925423 hasConcept C2778041864 @default.
• W4282925423 hasConcept C2778461978 @default.
• W4282925423 hasConcept C2778729363 @default.

• next